nogapendekin alfa inbakicept-pmln (Anktiva)
nogapendekin alfa inbakicept-pmln is an FDA-licensed reference biologic from Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2024
Reference approved
Reference product
Anktiva nogapendekin alfa inbakicept-pmln
Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.
- Approved
- Apr 22, 2024
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for nogapendekin alfa inbakicept-pmln, in chronological order.
Reference approval
Approval date of the reference nogapendekin alfa inbakicept-pmln product.
2 yr 2 mo ago
Frequently asked questions
Are there biosimilars approved for nogapendekin alfa inbakicept-pmln (Anktiva)?
No 351(k) biosimilars or interchangeable biosimilars referencing nogapendekin alfa inbakicept-pmln are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.